Validating Reward-related Biomarkers (RTOC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-16

Study Completion Date

2021-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Deficits or abnormalities in reward processing are present in a number of psychiatric disorders. The overarching objective of the study is to conduct initial validation work towards optimising three experimental tasks - which have previously been shown to be sensitive to reward processing deficits - for future use in clinical trials.

This initial validation work has the primary objective to uncover group differences in task outcome measures between healthy control participants, participants with Major Depressive Disorder (MDD) and participants with schizophrenia (SZ) using statistical analyses. This may provide some indications for the use of these tasks as clinically-relevant biomarkers.

Primary aims include:

(i) comparing the investigator's endpoint means and distributions to those in previously published data; (ii) replication of previously-reported differences between MDD/SZ vs. healthy control participants, and, (iii) exploring the relationship between task endpoints and subjective participant- and clinician-rated report of reward-related constructs (e.g. anhedonia, negative symptoms).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dopamine Function and Reward Processing In Schizophrenia

NCT01035996

Schizophrenia

COMPLETED

Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia

NCT01555697

Schizophrenia

COMPLETED PHASE1/PHASE2

A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

NCT03319953

Stable Schizophrenia

COMPLETED PHASE2

Virtual Rehabilitation for the Treatment of Motivational Deficits in Schizophrenia

NCT02709733

Schizophrenia

COMPLETED NA

Externalization and Stimulation

NCT05936307

Healthy Participants

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Depression Motivation Anhedonia, Physical Anhedonia, Social Negative Symptoms With Primary Psychotic Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HV

Humans aged 20-55 without a diagnosis of a psychiatric and neurological disorder.

Self-rating Questionnaires

Intervention Type BEHAVIORAL

* Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)
* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)
* Behavioral avoidance/inhibition Scales (BIS/BAS)

Measures of Reward processing/reinforcement learning

Intervention Type BEHAVIORAL

* Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)
* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)
* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)

SZ

Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of Schizophrenia.

Self-rating Questionnaires

Intervention Type BEHAVIORAL

* Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)
* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)
* Behavioral avoidance/inhibition Scales (BIS/BAS)

Measures of Reward processing/reinforcement learning

Intervention Type BEHAVIORAL

* Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)
* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)
* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)

Additional Schizophrenia-specific Questionnaires and Interviews

Intervention Type BEHAVIORAL

* Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)
* Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)

MDD

Humans aged 20-55 with a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of MDD.

Self-rating Questionnaires

Intervention Type BEHAVIORAL

* Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)
* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)
* Behavioral avoidance/inhibition Scales (BIS/BAS)

Measures of Reward processing/reinforcement learning

Intervention Type BEHAVIORAL

* Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)
* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)
* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Self-rating Questionnaires

* Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)
* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)
* Behavioral avoidance/inhibition Scales (BIS/BAS)

Intervention Type BEHAVIORAL

Measures of Reward processing/reinforcement learning

* Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)
* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)
* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)

Intervention Type BEHAVIORAL

Additional Schizophrenia-specific Questionnaires and Interviews

* Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)
* Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

General:

1. Be able to provide signed and dated informed consent for study participation.
2. Be male or female, aged between 20 and 55 years, inclusive.
3. Be able to read, write, and speak the language in which psychometric tests are provided, with acceptable visual and auditory acuity (corrected if necessary).
4. Unless otherwise stated, CNS medications to treat symptoms of MDD or SZ and other stable CNS conditions requiring medication is permitted in the MDD and SZ groups, provided the daily dose of medication has not been changed by more than +/- 30% in the last 4 weeks before the start of the study, and is not expected to change by a larger fraction while participating in the study.

MDD

Participants must:

1. Have a primary Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnosis of MDD, confirmed by the result of the MINI interview conducted by the site at screening. Subjects with a diagnosis of comorbid Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder or specific phobia may be included.
2. Meet the DSM-5 criteria for a current Major Depressive Episode, with the current depressive episode not having lasted longer than 6 months.
3. If undergoing treatment, be currently treated with an antidepressant approved in this protocol for at least 4 continuous weeks. Psychological treatments (e.g., Cognitive Behaviour Therapy, Interpersonal Psychotherapy, Psychodynamic Psychotherapy etc.) are all permitted in this study regardless of frequency and duration.

SZ

Subjects must:

1. Have a primary diagnosis of schizophrenia according to the Statistical Manual of Mental Disorders 5th edition (DSM-5), confirmed by the result of the MINI interview conducted by the site at screening. Subjects with a diagnosis of comorbid Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder or specific phobia may be included.
2. Dose of antipsychotics not exceeding the equivalent of 6 mg risperidone.

Minimum Eligible Age

20 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes